Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535727 · ClinicalTrials.gov registry record · Phase 1
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03535727 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 48 participants.
The verdict
NCT03535727, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Irinotecan
- DRUG Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03535727
The ClinicalTrials.gov registry entry for NCT03535727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT03535727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03535727 about?
NCT03535727 is a clinical study titled "A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer". The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
What is the current status of trial NCT03535727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-06-21. Estimated completion is 2022-10-03.
What interventions are being tested in trial NCT03535727?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Irinotecan (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03535727?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.